Review decision – September 2018
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA343; Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia and TA344; Ofatumumab in combination with chlorambucil or bendamustine for previously untreated chronic lymphocytic leukaemia.
There are no new cost or clinical effectiveness data for obinutuzumab or ofatumumab, which would warrant reconsideration of the existing recommendations.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently TA343 and TA344 will move to the ‘static list’ of technology appraisals.
This page was last updated: